Treating inflammation to improve depression in HIV
Treatments studied
Part of Brain & nervous system, Immune system & allergy, Infections clinical trials.
This Phase 2 study looks at whether lowering inflammation can help improve depression symptoms in adults living with HIV. You may be able to join if your HIV is well controlled and you are currently experiencing major depression (or a certain type of bipolar depression).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 65 years old
- Your HIV is controlled: on the same HIV medicines (ART) with viral load under 200 for at least 12 months
- Your immune system is steady: CD4 count over 350 for at least 12 months
- You currently have major depression (or bipolar depressed type) confirmed by an interview, and your PHQ-9 depression score is 10 or higher
- Your recent depression is not being treated right now (or you’re on the same stable mood medicine regimen for at least 4–8 weeks, depending on the drug)
- Your body shows inflammation: C-reactive protein (CRP) is 2 mg/L or higher
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a pill called baricitinib (already used for arthritis) to see if adding it to your HIV medications can help control the virus long-term. You might join if your HIV is well controlled and you are generally healthy.
This study tests if cognitive behavioral therapy (a type of talk therapy) can improve how your body handles sugar (insulin resistance) for people living with HIV who also have depression. You may join if you have HIV, are on stable HIV meds, feel depressed, and do not have diabetes.
This study looks at how depression and its treatment may affect the brain and immune-related body systems in people with HIV. You may be eligible if you have depression and a well-controlled HIV viral load, and you can safely complete brain MRI scans.
This study tests a program that helps people with HIV manage depression and stick to their treatment. It's for adults in Cape Town, South Africa, who have a detectable HIV viral load or may have one, and who show signs of depression.
This trial studies how the HIV drug dolutegravir works in people who also have depression. Participants will receive an antidepressant called fluoxetine to see how it affects the HIV treatment.
This Phase 2 trial tests a brain-acting steroid called pregnenolone to help reduce depressed mood. It studies whether it can improve mood in adults with HIV who are already on HIV treatment and still have depression symptoms.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.